Development status and future prospects for a vaccine against Chlamydia trachomatis infection

Vaccine

Volumn 32, Issue 14, 2014, Pages 1563-1571

  Hafner, Louise M ^a   Wilson, David P ^b   Timms, Peter ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chlamydia; Vaccines; WHO special issue

Indexed keywords

BACTERIAL VACCINE; GAMMA INTERFERON;

ARTICLE; BACTERIAL VIRULENCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; FEMALE INFERTILITY; GENETIC TRANSFORMATION; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOLOGY; IN VITRO STUDY; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PLASMID; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; T LYMPHOCYTE;

CHLAMYDIA; VACCINES; WHO SPECIAL ISSUE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON-GAMMA; TRANSFORMATION, GENETIC; VACCINATION;

EID: 84896726091     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.020     Document Type: Article

References (137)

1. Hafner L.M., Pelzer E.S. Tubal damage, infertility and tubal ectopic pregnancy: Chlamydia trachomatis and other microbial aetiologies. Ectopic pregnancy - modern diagnosis and management 2011, InTech, Rijeka, Croatia. M. Kamrava (Ed.).
2. World Health Organization Global prevalence and incidence of selected curable sexually transmitted infections 2008, World Health Organization, Geneva.
3. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
4. Owusu-Edusei K., Doshi S.R., Apt B.S., Gift T.L. The direct cost of chlamydial infections: estimates for the employer-sponsored privately insured population in the United States, 2003-2007. Sex Transm Dis 2010, 37:519-521.
5. Haggerty C.L., Gottlieb S.L., Taylor B.D., Low N., Xu F., Ness R.B. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010, 201(Suppl. 2):S134-S155.
6. Rosenman M.B., Mahon B.E., Downs S.M., Kleiman M.B. Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to Chlamydia trachomatis. Arch Pediatr Adolesc Med 2003, 157:565-571.
7. Institute of Medicine (US) Committee to Study Priorities for Vaccine Development Vaccines for the 21st century: a tool for decisionmaking 2000, National Academy Press, Washington, DC.
8. Brill J.R. Diagnosis and treatment of urethritis in men. Am Fam Physician 2010, 81:873-878.
9. Wetmore C.M., Manhart L.E., Lowens M.S., Golden M.R., Whittington W.L.H., Xet-Mull A.M., et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011, 38:180-186.
10. Tracy C.R., Steers W.D., Costabile R. Diagnosis and management of epididymitis. Urol Clin North Am 2008, 35:101-108. vii.
11. Mulcahy F.M., Bignell C.J., Rajakumar R., Waugh M.A., Hetherington J.W., Ewing R., et al. Prevalence of chlamydial infection in acute epididymo-orchitis. Genitourin Med 1987, 63:16-18.
12. Karam G.H., Martin D.H., Flotte T.R., Bonnarens F.O., Joseph J.R., Mroczkowski T.F., et al. Asymptomatic Chlamydia trachomatis infections among sexually active men. J Infect Dis 1986, 154:900-903.
13. Stamm W.E. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999, 179(Suppl. 2):S380-S383.
14. Stamm W.E. Lymphogranuloma venereum. Sexually transmitted diseases 2008, 4:595-605.
15. Gottlieb S.L., Low N., Newman L.M., Bolan G., Kamb M., Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 2014, 32:1527-1535.
16. Roberts T.E., Robinson S., Barton P., Bryan S., Low N. Chlamydia screening studies G. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Infect 2006, 82:193-200. [discussion 1].
17. Campbell R., Mills N., Sanford E., Graham A., Low N., Peters T.J., et al. Does population screening for Chlamydia trachomatis raise anxiety among those tested? Findings from a population based chlamydia screening study. BMC Public Health 2006, 6:106.
18. Low N., McCarthy A., Macleod J., Salisbury C., Campbell R., Roberts T.E., et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007, 11:1-165. iii-iv, ix-xii.
19. Guy R.J., Ali H., Liu B., Poznanski S., Ward J., Donovan B., et al. Efficacy of interventions to increase the uptake of chlamydia screening in primary care: a systematic review. BMC Infect Dis 2011, 11:211.
20. Kong F.Y., Guy R.J., Hocking J.S., Merritt T., Pirotta M., Heal C., et al. Australian general practitioner chlamydia testing rates among young people. Med J Aust 2011, 194:249-252.
21. Tao G., Hoover K.W., Leichliter J.S., Peterman T.A., Kent C.K. Self-reported Chlamydia testing rates of sexually active women aged 15-25 years in the United States, 2006-2008. Sex Transm Dis 2012, 39:605-607.
22. Turner K., Adams E., Grant A., Macleod J., Bell G., Clarke J., et al. Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. BMJ 2011, 342:c7250.
23. Regan D.G., Wilson D.P., Hocking J.S. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis 2008, 198:349-358.
24. Turner K.M., Adams E.J., Gay N., Ghani A.C., Mercer C., Edmunds W.J. Developing a realistic sexual network model of chlamydia transmission in Britain. Theor Bio Med Model 2006, 3:3.
25. Turner K.M., Adams E.J., Lamontagne D.S., Emmett L., Baster K., Edmunds W.J. Modelling the effectiveness of chlamydia screening in England. Sex Transm Infect 2006, 82:496-502.
26. Golden M.R., Whittington W.L., Handsfield H.H., Hughes J.P., Stamm W.E., Hogben M., et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.
27. Lau C.Y., Qureshi A.K. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002, 29:497-502.
28. Schwebke J.R., Rompalo A., Taylor S., Sena A.C., Martin D.H., Lopez L.M., et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011, 52:163-170.
29. LaMontagne D.S., Baster K., Emmett L., Nichols T., Randall S., McLean L., et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect 2007, 83:292-303.
30. Walker J., Tabrizi S.N., Fairley C.K., Chen M.Y., Bradshaw C.S., Twin J., et al. Chlamydia trachomatis incidence and re-infection among young women-behavioural and microbiological characteristics. PLoS ONE 2012, 7:e37778.
31. Brunham R.C., Pourbohloul B., Mak S., White R., Rekart M.L. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005, 192:1836-1844.
32. Vicetti Miguel R.D., Reighard S.D., Chavez J.M., Rabe L.K., Maryak S.A., Wiesenfeld H.C., et al. Transient detection of chlamydial-specific Th1 memory cells in the peripheral circulation of women with history of Chlamydia trachomatis genital tract infection. Am J Reprod Immunol 2012, 68:499-506.
33. Fisher W.A. Understanding human papillomavirus vaccine uptake. Vaccine 2012, 30(Suppl. 5):F149-F156.
34. Kessels S.J., Marshall H.S., Watson M., Braunack-Mayer A.J., Reuzel R., Tooher R.L. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012, 30:3546-3556.
35. Abdelrahman Y.M., Belland R.J. The chlamydial developmental cycle. FEMS Microbiol Rev 2005, 29:949-959.
36. Ward M.E. Chlamydial classification, development and structure. Br Med Bull 1983, 39:109-115.
37. Schachter J., Stephens R.S. Biology of Chlamydia trachomatis. Sexually transmitted diseases 2008, 555-574. McGraw Hill Professional, USA. 4th ed. K.K. Holmes, F.P. Sparling (Eds.).
38. Hybiske K., Stephens R.S. Exit strategies of intracellular pathogens. Nat Rev Microbiol 2008, 6:99-110.
39. Schoborg R.V. Chlamydia persistence-a tool to dissect chlamydia-host interactions. Microbes Infect 2011, 13:649-662.
40. Wyrick P.B., Knight S.T. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J Antimicrob Chemother 2004, 54:79-85.
41. Geisler W.M. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010, 201(Suppl. 2):S104-S113.
42. Hafner L.M., Timms P. Chlamydia sexually transmitted diseases: vaccines, prevention, and control 2013, 369-410. Elsevier Ltd., USA. 2nd ed. L.R. Stanberry, S.L. Rosenthal (Eds.).
43. Beagley K.W., Huston W.M., Hansbro P.M., Timms P. Chlamydial infection of immune cells: altered function and implications for disease. Crit Rev Immunol 2009, 29:275-305.
44. Cheng W., Shivshankar P., Zhong Y., Chen D., Li Z., Zhong G. Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor. Infect Immun 2008, 76:942-951.
45. Hickey D.K., Patel M.V., Fahey J.V., Wira C.R. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011, 88:185-194.
46. Rasmussen S.J., Eckmann L., Quayle A.J., Shen L., Zhang Y.X., Anderson D.J., et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997, 99:77-87.
47. Agrawal T., Vats V., Salhan S., Mittal A. Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis. Clin Exp Immunol 2007, 148(3):461-468.
48. Geisler W.M., Morrison S.G., Doemland M.L., Iqbal S.M., Su J., Mancevski A., et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis 2012, 206:1836-1843.
49. Ghaem-Maghami S., Ratti G., Ghaem-Maghami M., Comanducci M., Hay P.E., Bailey R.L., et al. Mucosal and systemic immune responses to plasmid protein pgp3 in patients with genital and ocular Chlamydia trachomatis infection. Clin Exp Immunol 2003, 132(3):436-442.
50. Bastidas R.J., Elwell C.A., Joanne N., Engel J.N., Raphael H., Valdivia R.H. Chlamydial intracellular survival strategies. Cold Spring Harb Perspect Med 2013, 10.1101/cshperspect.a010256.
51. Reddy B.S., Rastogi S., Verma S., Das B., Salhan S/, Mittal A. Cytokine expression pattern in the genital tract of C. trachomatis positive infertile women-implication for T cell responses. Clin Exp Immunol 2004, 137:552-558.
52. Rottenberg M.E., Gigliotti-Rothfuchs A., Wigzell H. The role of IFN-gamma in the outcome of chlamydial infection. Curr Opin Immunol 2002, 14:444-451.
53. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(2):149-161.
54. Lad S.P., Li J., da Silva Correia J., Pan Q., Gadwal S., Ulevitch R.J., et al. Cleavage of p65/RelA of the NF-kB pathway by Chlamydia. Proc Natl Acad Sci 2007, 104:2933-2938.
55. Song L., Carlson J.H., Whitmire W.M., Kari L., Virtaneva K., Sturdevant D.E., et al. Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes. Infect Immun 2013, 81(March (3)):636-644.
56. Zhong G., Fan T., Liu L.I. Chlamydia inhibits interferon γ-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999, 189(12):1931-1937.
57. Zhong G., Liu L., Fan T., Fan P., Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000, 191(May (9)):1525-1534.
58. Ibana J.A., Schust D.J., Sugimato J., Nagamatsu T., Greene S.J., Quayle A.J. Chlamydia trachomatis immune evasion via downregulation of MHC class i surface expression involves direct and indirect mechanisms. Inf Dis Obstet Gynecol 2011, 2011. [Article ID 420905, 8 pages]. 10.1155/2011/420905.
59. Taylor B.D., Darville T., Ferrell R.E., Kammerer C.M., Ness R.B., Haggerty C.L. Variants in Toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease. J Infect Dis 2012, 205:603-609.
60. Wira C.R., Rodríguez-García M., Patel M.V. Mucosal immunity in the human reproductive tract: balancing reproductive potential with protection against sexually transmitted pathogens. Sexually transmitted diseases: vaccines, prevention, and control 2013, 71-110. Elsevier Ltd., USA. 2nd ed. L.R. Stanberry, S.L. Rosenthal (Eds.).
61. Hanna N.F., Taylor-Robinson D., Kalodiki-Karamanoli M., Harris J.R., McFadyen I.R. The relation between vaginal pH and the microbiological status in vaginitis. Br J Obstet Gynaecol 1985, 92:1267-1271.
62. Clarke M.A., Rodriguez A.C., Gage J.C., Herrero R., Hildesheim A., Wacholder S., et al. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis 2012, 12:33.
63. Brotman R.M., Ravel J., Baviol P.M., Gravitt P.E., Ghanem K.G. Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections. Vaccine 2014, 32:1543-1552.
64. Carey A.J., Cunningham K.A., Hafner L.M., Timms P., Beagley K.W. Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunol Cell Biol 2009, 87:337-343.
65. Blazar A.S., Hogan J.W., Seifer D.B., Frishman G.N., Wheeler C.A., Haning R.V. The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization. Fertil Steril 1997, 67(3):517-520.
66. Rank R.G., Sanders M.M. Pathogenesis of endometritis and salpingitis in a guinea pig model of chlamydial genital infection. Am J Pathol 1992, 140:927-936.
67. Molano M., Meijer C.J., Weiderpass E., Arslan A., Posso H., Franceschi S., et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005, 191:907-916.
68. Ito J.I., Lyons J.M., Airo-Brown L.P. Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection. Infect Immun 1990, 58:2021-2023.
69. Nelson D.E., Virok D.P., Wood H., Roshick C., Johnson R.M., Whitmire W.M., et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc Natl Acad Sci USA 2005, 102:10658-10663.
70. Beatty W.L., Belanger T.A., Desai A.A., Morrison R.P., Byrne G.I. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994, 62:3705-3711.
71. Morrison S.G., Su H., Caldwell H.D., Morrison R.P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun 2000, 68:6979-6987.
72. Perry L.L., Feilzer K., Caldwell H.D. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol 1997, 158:3344-3352.
73. Ramsey K.H., Sigar I.M., Schripsema J.H., Shaba N., Cohoon K.P. Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect Immun 2005, 73:6962-6973.
74. Stephens R.S. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 2003, 11:44-51.
75. Rank R.G., Sanders M.M., Patton D.L. Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. Sex Transm Dis 1995, 22:48-54.
76. Van Voorhis W.C., Barrett L.K., Sweeney Y.T., Kuo C.C., Patton D.L. Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring. Infect Immun 1997, 65:2175-2182.
77. Bell J.D., Bergin I.L., Schmidt K., Zochowski M.K., Aronoff D.M., Patton D.L. Nonhuman primate models used to study pelvic inflammatory disease caused by Chlamydia trachomatis. Infect Dis Obstet Gynecol 2011, 2011:675360.
78. Cheng C., Pal S., Bettahi I., Oxford K.L., Barry P.A., de la Maza L.M. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine 2011, 29:3456-3464.
79. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182:8063-8070.
80. Kari L., Whitmire W.M., Olivares-Zavaleta N., Goheen M.M., Taylor L.D., Carlson J.H., et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011, 208:2217-2223.
81. Bell J.D., Bergin I.L., Harris L.H., Chai D., Mullei I., Mwenda J., et al. The effects of a single cervical inoculation of Chlamydia trachomatis on the female reproductive tract of the baboon (Papio anubis). J Infect Dis 2011, 204:1305-1312.
82. Patton D.L., Kuo C.C., Wang S.P., Halbert S.A. Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques. J Infect Dis 1987, 155:1292-1299.
83. Henning T., Fakile Y., Phillips C., Sweeney E., Mitchell J., Patton D., et al. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol 2011, 40:214-223.
84. Grayston J.T., Wang S.P., Yang Y.F., Woolridge R.L. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J Exp Med 1962, 115:1009-1022.
85. Mabey D., Hu V., Bailey R., Burton M., Holland M. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine 2014, 32:1572-1578.
86. Carey A., Cunningham K., Andrew D., Hafner L., Timms P., Beagley K. A comparison of the effects of a chlamydial vaccine administered during or after a C. muridarum urogenital infection of female mice. Vaccine 2011, 29:6505-6513.
87. Geisler W.M., Lensing S.Y., Press C.G., Hook E.W. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013, 207(12):1850-1856. [Advance access published].
88. Karunakaran K.P., Yu H., Foster L.J., Brunham R.C. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccin 2010, 6:676-680.
89. Alving C.R., Peachman K.K., Rao M., Reed S.G. Adjuvants for human vaccines. Curr Opin Immunol 2012, 24:310-315.
90. Dong-Ji Z., Yang X., Shen C., Lu H., Murdin A., Brunham R.C. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun 2000, 68:3074-3078.
91. Pal S., Peterson E.M., Rappuoli R., Ratti G., de la Maza L.M. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 2006, 24:766-775.
92. He Q., Martinez-Sobrido L., Eko F.O., Palese P., Garcia-Sastre A., Lyn D., et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology 2007, 122:28-37.
93. Macmillan L., Ifere G.O., He Q., Igietseme J.U., Kellar K.L., Okenu D.M., et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol 2007, 49:46-55.
94. Hansen J., Jensen K.T., Follmann F., Agger E.M., Theisen M., Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis 2008, 198:758-767.
95. O'Meara C., Armitage C., Harvie M., Timms P., Lycke N., Beagley K. Immunization with a MOMP-based vaccine protects against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS ONE 2013, 8(4):e61962. 10.1371/journal.pone.0061962.
96. World Health Organization Immunization, vaccines and biologicals 2013, World Health Organization, Geneva, http://www.who.int/immunization/topics/en/index.html.
97. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J Am Med Assoc 1994, 271:698-702.
98. Fraser A., Goldberg E., Acosta C.J., Paul M., Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007, CD001261.
99. Graves P.M., Deeks J.J., Demicheli V., Jefferson T. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected). Cochrane Database Syst Rev 2010, CD000974.
100. World Health Organization Cholera vaccines: WHO position paper. Weekly epidemiological record 2001, April, vol. 76:117-124. World Health Organization, Geneva, http://www.who.int/immunization/wer7616cholera_Apr01_position_paper.pdf.
101. World Health Organization Development of a vaccine effective against avian influenza H5N1 infection in humans. Weekly epidemiological record 2004, January, vol. 79:25-40. World Health Organization, Geneva, http://www.who.int/wer/2004/en/wer7904.pdf.
102. Garnett G.P. The theoretical impacts of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014, 32:1536-1542.
103. Amirfar S., Hollenberg J.P., Abdool Karim S.S. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006, 43:219-225.
104. Anderson R.M., Swinton J., Garnett G.P. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc Biol Sci 1995, 261:147-151.
105. Andersson K.M., Owens D.K., Vardas E., Gray G.E., McIntyre J.A., Paltiel A.D. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. J Acquir Immune Defic Syndr 2007, 46:78-90.
106. Blower S.M., Koelle K., Kirschner D.E., Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA 2001, 98:3618-3623.
107. Blower S.M., McLean A.R. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994, 265:1451-1454.
108. Johnson L.F., Bekker L.G., Dorrington R.E. HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited. Vaccine 2007, 25:7502-7509.
109. Kaldor J.M., Wilson D.P. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision. AIDS 2010, 24:2573-2578.
110. McLean A.R., Blower S.M. Imperfect vaccines and herd immunity to HIV. Proc Biol Sci 1993, 253:9-13.
111. Choi Y.H., Chapman R., Gay N., Jit M. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine 2012, 30:3383-3388.
112. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896-904.
113. Kim J.J. Mathematical model of HPV provides insight into impacts of risk factors and vaccine. PLoS Med 2006, 3:e164.
114. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28:5473-5484.
115. Hankins C.A., Glasser J.W., Chen R.T. Modeling the impact of RV144-like vaccines on HIV transmission. Vaccine 2011, 29:6069-6071.
116. MIDAS: Models of Infectious Disease Agent Study 2013, https://www.epimodels.org/midas/modelProfilesFull.do.
117. Althaus C.L., Turner K.M., Schmid B.V., Heijne J.C., Kretzschmar M., Low N. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. J R Soc Interface 2012, 9:136-146.
118. Gray R.T., Beagley K.W., Timms P., Wilson D.P. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009, 199:1680-1688.
119. Rockey D.D. Unraveling the basic biology and clinical significance of the chlamydial plasmid. J Exp Med 2011, 208:2159-2162.
120. O'Connell C.M., AbdelRahman Y.M., Green E., Darville H.K., Saira K., Smith B., et al. Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum. Infect Immun 2011, 79:1044-1056.
121. O'Connell C.M., Ingalls R.R., Andrews C.W., Scurlock A.M., Darville T. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 2007, 179:4027-4034.
122. Wang Y., Kahane S., Cutcliffe L.T., Skilton R.J., Lambden P.R., Clarke I.N. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011, 7:e1002258.
123. Eko F.O., Ekong E., He Q., Black C.M., Igietseme J.U. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine 2011, 29:1472-1480.
124. Wang J., Chen L., Chen F., Zhang X., Zhang Y., Baseman J., et al. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine 2009, 27:2967-2980.
125. Picard M.D., Cohane K.P., Gierahn T.M., Higgins D.E., Flechtner J.B. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 2012, 30:4387-4393.
126. Schautteet K., De Clercq E., Jonsson Y., Lagae S., Chiers K., Cox E., et al. Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization. Vaccine 2012, 30:2869-2881.
127. Comanducci M., Manetti R., Bini L., Santucci A., Pallini V., Cevenini R., et al. Humoral immune response to plasmid protein Pgp3 in patients with Chlamydia trachomatis infection. Infect Immun 1994, 62:5491-5497.
128. Molina D.M., Pal S., Kayala M.A., Teng A., Kim P.J., Baldi P., et al. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine 2010, 28:3014-3024.
129. Finco O., Frigimelica E., Buricchi F., Petracca R., Galli G., Faenzi E., et al. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci 2011, 108:9969-9974.
130. Coler R.N., Bhatia A., Maisonneuve J.F., Probst P., Barth B., Ovendale P., et al. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol 2009, 55:258-270.
131. Meoni E., Faenzi E., Frigimelica E., Zedda L., Skibinski D., Giovinazzi S., et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun 2009, 77:4168-4176.
132. Follmann F., Olsen A.W., Jensen K.T., Hansen P.R., Andersen P., Theisen M. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J Infect Dis 2008, 197:897-905.
133. Goodall J.C., Yeo G., Huang M., Raggiaschi R., Gaston J.S. Identification of Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an expression library. Eur J Immunol 2001, 31:1513-1522.
134. Murthy A.K., Cong Y., Murphey C., Guentzel M.N., Forsthuber T.G., Zhong G., et al. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun 2006, 74:6722-6729.
135. Barker C.J., Beagley K.W., Hafner L.M., Timms P. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 2008, 26:1285-1296.
136. Agrawal T., Vats V., Salhan S., Mittal A. Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis. Clin Exp Immunol 2007, 148:461-468.
137. Portig I., Goodall J.C., Bailey R.L., Gaston J.S. Characterization of the humoral immune response to Chlamydia outer membrane protein 2 in chlamydial infection. Clin Diag Lab Immunol 2003, 10:103-107.